» Authors » Ruth L Ladenstein

Ruth L Ladenstein

Explore the profile of Ruth L Ladenstein including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 210
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Flaadt T, Rehm J, Simon T, Hero B, Ladenstein R, Lode H, et al.
Cancers (Basel) . 2025 Jan; 17(1. PMID: 39796776
Background: The incorporation of anti-GD2 antibodies such as ch14.18/SP2/0 into the multimodal treatment of high-risk neuroblastoma (HR-NB) patients has improved their outcomes. As studies assessing the long-term outcomes, long-term sequelae,...
2.
Stork T, Ranft A, Aigner C, Jurgens H, Ladenstein R, Timmermann B, et al.
Cancers (Basel) . 2025 Jan; 17(1. PMID: 39796745
Objective: Ewing sarcoma (EWS) of the mediastinum is extremely rare, with only a few cases reported in the literature. We aimed to gain a better understanding of primary mediastinal EWS,...
3.
Flaadt T, Ebinger M, Schreiber M, Ladenstein R, Simon T, Lode H, et al.
J Clin Med . 2023 Oct; 12(19). PMID: 37834840
Despite highly intensive multimodality treatment regimens, the prognosis of patients with high-risk neuroblastoma (HRNB) and central nervous system (CNS) relapse remains poor. We retrospectively reviewed data from 13 patients with...
4.
Flaadt T, Ladenstein R, Ebinger M, Lode H, Arnardottir H, Poetschger U, et al.
J Clin Oncol . 2023 Feb; 41(17):3135-3148. PMID: 36854071
Purpose: Patients with relapsed high-risk neuroblastoma (rHR-NB) have a poor prognosis. We hypothesized that graft-versus-neuroblastoma effects could be elicited by transplantation of haploidentical stem cells (haplo-SCT) exploiting cytotoxic functions of...
5.
Park J, Villablanca J, Hero B, Kushner B, Wheatley K, Beiske K, et al.
Cancer . 2022 Sep; 128(21):3775-3783. PMID: 36101004
Background: International standardized criteria for eligibility, evaluable disease sites, and disease response assessment in patients with refractory, progressive, or relapsed high-risk neuroblastoma enrolled in early-phase clinical trials are lacking. Methods:...
6.
Yanik G, Parisi M, Naranjo A, Nadel H, Gelfand M, Park J, et al.
J Nucl Med . 2017 Sep; 59(3):502-508. PMID: 28887399
A semiquantitative I-metaiodobenzylguanidine (I-MIBG) scoring method (the Curie score, or CS) was previously examined in the Children's Oncology Group (COG) high-risk neuroblastoma trial, COG A3973, with a postinduction CS of...
7.
Bogen D, Brunner C, Walder D, Ziegler A, Abbasi R, Ladenstein R, et al.
Int J Cancer . 2016 Feb; 139(1):153-63. PMID: 26910568
Amplification of MYCN is the signature genetic aberration of 20-25% of neuroblastoma and a stratifying marker associated with aggressive tumor behavior. The detection of heterogeneous MYCN amplification (hetMNA) poses a...
8.
London W, Castel V, Monclair T, Ambros P, Pearson A, Cohn S, et al.
J Clin Oncol . 2011 Jul; 29(24):3286-92. PMID: 21768459
Purpose: Survival after neuroblastoma relapse is poor. Understanding the relationship between clinical and biologic features and outcome after relapse may help in selection of optimal therapy. Our aim was to...